Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 13/20 | 1.00 |
| ▸ | PKLR | P30613 | 4/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 0.71 |
| ▸ | RAB9A | P51151 | 1/20 | 0.71 |
| ▸ | HTT | P42858 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19871300 | 1.00 | PKM (1.00) | PKMPKLRNPC1RAB9AHTT | |
| SCHEMBL1725495 | 1.00 | PKM (1.00) | PKMPKLRNPC1RAB9AHTT | |
| SCHEMBL17808925 | 1.00 | PKM (1.00) | PKMPKLRNPC1RAB9AHTT | |
| SCHEMBL19858525 | 0.88 | PKM (0.77) | PKMPKLRNPC1RAB9AHTT | |
| SCHEMBL20457189 | 0.86 | PKM (0.75) | PKMPKLRNPC1RAB9A | |
| SCHEMBL31315853 | 0.84 | PKM (1.00) | PKMPKLRNPC1RAB9AHTT | |
| SCHEMBL1722721 | 0.84 | PKM (1.00) | PKMPKLRNPC1RAB9AHTT | |
| SCHEMBL23598057 | 0.84 | PKM (0.73) | PKMPKLRNPC1RAB9AHTT | |
| SCHEMBL20456955 | 0.84 | PKM (0.73) | PKMPKLRHTTALDH1A1 | |
| SCHEMBL19871299 | 0.84 | PKM (0.73) | PKMPKLRHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4081257-A1 | METHODS OF NORMALIZING ABERRANT GLYCOLYTIC METABOLISM IN CANCER CELLS | The Board of Trustees of the Leland Stanford Junior University (US) | 2022-11-02 | — | — | EP | disclosed |
| CN-115243720-A | Method for normalizing abnormal glycolytic metabolism in cancer cells | 利兰·斯坦福青年大学托管委员会 | 2022-10-25 | — | — | CN | disclosed |